Literature DB >> 12830451

The association of nephrolithiasis with cystic fibrosis.

Eric M Gibney1, David S Goldfarb.   

Abstract

BACKGROUND: There is a growing body of evidence regarding the association between cystic fibrosis (CF) and nephrolithiasis and the role that Oxalobacter formigenes may have in that association.
METHODS: We performed a MEDLINE search of "cystic fibrosis and nephrolithiasis" and "Oxalobacter formigenes." Epidemiological and experimental evidence and possible mechanisms explaining the association were critically reviewed.
RESULTS: Of patients with CF, 3.0% to 6.3% are affected with nephrolithiasis, a percentage greater than that of age-matched controls without CF, in whom the rate is 1% to 2%. Studies have suggested possible mechanisms for the association, including hyperuricosuria, hyperoxaluria, primary defects in calcium handling caused by mutation of the CF transmembrane regulator (CFTR), hypocitraturia, and lack of colonization with O formigenes, an enteric oxalate-degrading bacterium. The absence of colonization could be related to frequent courses of antibiotics.
CONCLUSION: Although the incidence of stones in patients with CF may be increased compared with controls without CF, many possible mechanisms are implicated. The relative contributions of these mechanisms remain uncertain. Future directions may include specific identification of lithogenic risks and therapy aimed at stone prevention in this population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12830451     DOI: 10.1016/s0272-6386(03)00403-7

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  19 in total

Review 1.  Chloride channel diseases resulting from impaired transepithelial transport or vesicular function.

Authors:  Thomas J Jentsch; Tanja Maritzen; Anselm A Zdebik
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

2.  Routine OGTT screening for CFRD - no thanks.

Authors:  Martin Walshaw
Journal:  J R Soc Med       Date:  2009-07       Impact factor: 5.344

3.  N-glycosylation critically regulates function of oxalate transporter SLC26A6.

Authors:  R Brent Thomson; Claire L Thomson; Peter S Aronson
Journal:  Am J Physiol Cell Physiol       Date:  2016-09-28       Impact factor: 4.249

Review 4.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

Review 5.  The use of antibiotics and risk of kidney stones.

Authors:  Shivam Joshi; David S Goldfarb
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

6.  Renal function in pediatric cystic fibrosis patients in the first decade of life.

Authors:  Chanel Prestidge; Mark A Chilvers; A George F Davidson; Eva Cho; Vanessa McMahon; Colin T White
Journal:  Pediatr Nephrol       Date:  2010-12-29       Impact factor: 3.714

7.  Bone involvement in young adults with cystic fibrosis awaiting lung transplantation for end-stage respiratory failure.

Authors:  E Cairoli; C Eller-Vainicher; L C Morlacchi; P Tarsia; V Rossetti; M Pappalettera; M Arosio; I Chiodini; F Blasi
Journal:  Osteoporos Int       Date:  2019-02-23       Impact factor: 4.507

Review 8.  Nephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney disease.

Authors:  Robert H Glew; Yijuan Sun; Bruce L Horowitz; Konstantin N Konstantinov; Marc Barry; Joanna R Fair; Larry Massie; Antonios H Tzamaloukas
Journal:  World J Nephrol       Date:  2014-11-06

Review 9.  Drug-Induced Kidney Stones and Crystalline Nephropathy: Pathophysiology, Prevention and Treatment.

Authors:  Michel Daudon; Vincent Frochot; Dominique Bazin; Paul Jungers
Journal:  Drugs       Date:  2018-02       Impact factor: 9.546

Review 10.  CFTR and defective endocytosis: new insights in the renal phenotype of cystic fibrosis.

Authors:  François Jouret; Olivier Devuyst
Journal:  Pflugers Arch       Date:  2008-10-07       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.